Intellia Therapeutics

Clinical trials sponsored by Intellia Therapeutics, explained in plain language.

Intellia Therapeutics NTLA NASDAQ

A gene-editing company using CRISPR technology to develop therapies for genetic diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Gene-Editing shot aims to halt rare nerve disease in phase 3 trial Results expected Jul 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 2 Not yet finished but already full! 4 Completed 1

Gene editing breakthrough? CRISPR therapy targets rare amyloidosis

Disease control Completed

This early-stage trial tests NTLA-2001, a CRISPR-based gene editing therapy, in 72 adults with hereditary ATTR amyloidosis—a condition where abnormal protein builds up in nerves or the heart. The treatment aims to turn off the faulty gene to reduce protein levels. The study focus…

Phase 1 • Sponsor: Intellia Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC

Intellia Therapeutics

Upcoming readouts

Gene editing breakthrough? CRISPR therapy targets rare amyloidosis